MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference

SARS-CoV-2 infection has led to several million deaths worldwide and ravaged the economies of many countries. Hence, developing therapeutics against SARS-CoV-2 remains a core priority in the fight against COVID-19. Most of the drugs that have received emergency use authorization for treating SARS-Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Durojaye, Olanrewaju Ayodeji, Okoro, Nkwachukwu Oziamara, Odiba, Arome Solomon, Nwanguma, Bennett Chima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141821/
https://www.ncbi.nlm.nih.gov/pubmed/37117213
http://dx.doi.org/10.1038/s41598-023-33024-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141821/
https://www.ncbi.nlm.nih.gov/pubmed/37117213
http://dx.doi.org/10.1038/s41598-023-33024-2

Ejemplares similares